Grifols (GIFLF) Other Non Operating Income (2010 - 2018)
Grifols (GIFLF) reported Other Non Operating Income of $4.2 million for Q2 2018, down 72.48% on a YoY basis from $15.4 million in Q2 2017, and down 72.48% quarter-over-quarter from $15.4 million in Q2 2017.
Grifols (GIFLF) Other Non Operating Income (2010 - 2018) Analysis & Trends
Grifols has reported Other Non Operating Income for 8 years, with the latest figure at $4.2 million in Q2 2018.
- For the quarter ending Q2 2018, Other Non Operating Income fell 72.48% year-over-year to $4.2 million; the trailing twelve-month figure through Jun 2018 stood at $27.7 million (down 8.75% YoY), and the FY2025 full-year result was -$64.0 million, changed 0.15% from the prior year.
- Other Non Operating Income for Q2 2018 stood at $4.2 million, down from $15.4 million in the prior quarter.
- The five-year high for Other Non Operating Income was $15.4 million in Q2 2017, with the low at -$9.7 million in Q4 2015.
- Historically, Other Non Operating Income has averaged $3.8 million across 4 years, with a median of $4.2 million in 2015.
- The largest YoY upside for Other Non Operating Income was 221.3% in 2016 against a maximum downside of 129.14% in 2016.
- Grifols' Other Non Operating Income stood at -$9.7 million in 2015, then surged by 171.95% to $7.0 million in 2016, then soared by 120.93% to $15.4 million in 2017, then slumped by 72.48% to $4.2 million in 2018.
- The last three Other Non Operating Income figures came in at $4.2 million (Q2 2018), $15.4 million (Q2 2017), and $7.0 million (Q4 2016), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn |
| 10 | Grifols | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 4.24 Mn |
| Jun 30, 2017 | 15.41 Mn |
| Dec 31, 2016 | 6.98 Mn |
| Sep 30, 2016 | 1.06 Mn |
| Jun 30, 2016 | 6.90 Mn |
| Mar 31, 2016 | -2.97 Mn |
| Dec 31, 2015 | -9.70 Mn |
| Sep 30, 2015 | 4.22 Mn |
| Jun 30, 2015 | 2.15 Mn |
| Mar 31, 2015 | 10.20 Mn |
| Sep 30, 2013 | 5.94 Mn |
| Jun 30, 2013 | -403,477.94 |
| Mar 31, 2013 | -6.46 Mn |
| Dec 31, 2012 | 4.42 Mn |
| Sep 30, 2012 | -67,532.92 |
| Jun 30, 2012 | 4.77 Mn |
| Mar 31, 2012 | -1,831.91 |
| Dec 31, 2011 | -8.98 Mn |
| Sep 30, 2011 | 1.55 Mn |
| Jun 30, 2011 | -1.35 Mn |